Verrica Pharmaceuticals (NasdaqGM:VRCA) Q3 2025 Earnings Call November 17, 2025 08:30 AM ET Company ParticipantsJayson Rieger - President and CEOStacy Ku - Biotechnology Equity ResearchKevin Gardner - Managing DirectorJohn Kirby - Interim CFOConference Call ParticipantsDennis Ding - VP and Equity Research AnalystNone - AnalystNone - AnalystOperatorGood morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals third quarter 2025 corporate update conference call. At this time, all participants ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q3 2025 Earnings Call November 17, 2025 08:30 AM ET Company ParticipantsJayson Rieger - President and CEOStacy Ku - Biotechnology Equity ResearchKevin Gardner - Managing DirectorJohn Kirby - Interim CFOConference Call ParticipantsDennis Ding - VP and Equity Research AnalystNone - AnalystNone - AnalystOperatorGood morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2025 Corporate Update Conference Call. At this time, all participants ...

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $14.3 million, a significant increase from negative revenue of $1.8 million in Q3 2024 [18] - Net YCANTH revenue for Q3 2025 was $3.6 million, compared to negative $1.9 million in Q3 2024, reflecting improved demand and sales [18][19] - GAAP net loss for Q3 2025 was $0.2 million, or $0.03 per share, compared to a GAAP net loss of $22.9 million, or $4.88 per share in Q3 2024 [21] - Non-GAAP net income for Q3 2025 was $1.2 million, or $0.13 per share, compared to a net loss of $20.2 million, or $4.30 per share in Q3 2024 [21] Business Line Data and Key Metrics Changes - Dispensed applicator units of YCANTH reached 14,093 in Q3 2025, representing approximately 5% sequential growth over the prior quarter [10] - Year-to-date dispensed applicator units increased to 37,642 for the nine months ended September 30, 2025, a 120% increase compared to the same period in 2024 [6] Market Data and Key Metrics Changes - The approval of YCANTH in Japan for molluscum is expected to lead to multiple approvals across major pharmaceutical markets, including the EU [8] - Feedback from the European Medicines Agency indicated no further phase III studies are needed for YCANTH's approval for molluscum, with a filing anticipated as early as Q4 2026 [8] Company Strategy and Development Direction - The company aims to establish YCANTH as a leading therapy for multiple types of skin lesions, leveraging its existing clinician relationships [6] - The development of VP-315 for basal cell carcinoma is positioned as a potential standard of care, with plans for a phase III study design confirmed by the FDA [10][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of YCANTH and the potential for VP-315, highlighting a strong foundation for future growth [4][17] - The company is focused on optimizing its cost structure while expanding its commercial strategy, which has led to reduced spending and increased product adoption [5][20] Other Important Information - The company received $18 million in cash milestone payments from Torii in 2025, with $10 million received in Q3 upon YCANTH's approval in Japan [7] - A new non-dispensing pharmacy, YCANTH Rx, is expected to launch in Q4 2025 to streamline the prescription process for healthcare providers [12][13] Q&A Session Summary Question: Can you further speak to the YCANTH demand that you're seeing in Q4? - Management noted that momentum from September has continued into Q4, with expectations for increased demand as the cold and flu season approaches [24][25] Question: What kind of counter-detailing are you seeing, and what has been the prescriber feedback on Zilretc? - Management views the Zilretc launch positively, as it raises awareness about the need to treat molluscum, while YCANTH remains a best-in-class option [25] Question: When do you expect sales force productivity to fully ramp? - It typically takes a few months for new sales representatives to become fully productive, with expectations for many to be effective early in 2026 [26][27] Question: Why is there a 12-month timeline for the EU filing despite no additional clinical trials required? - The timeline includes necessary sequential steps, such as securing a pediatric waiver, which adds time to the process [27][28] Question: What feedback has been received regarding YCANTH Rx? - Feedback has been positive, with the new pharmacy model expected to simplify the prescription process for clinicians and patients [29][30] Question: How should we think about seasonality impact in Q4 sales? - Traditional seasonal slowdowns are expected in November and December, but increased doctor visits during the cold and flu season may boost diagnoses of molluscum [32][33]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________ FORM 10-Q ______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission Fil ...

Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results – Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received $10 million cash milesto ...

Core Insights - Verrica Pharmaceuticals Inc. reported significant progress in its commercial and clinical activities, particularly with its product YCANTH for molluscum contagiosum, and highlighted a strong foundation for future growth [2][4]. Financial Performance - The company reported $14.3 million in total revenue for Q3 2025, which includes $3.6 million from YCANTH and $10.7 million from license and collaboration revenue [4][21]. - For the nine months ending September 30, 2025, product revenue was $11.6 million, up from $6.3 million in the same period in 2024 [11][15]. - The net loss for Q3 2025 was $0.3 million, or $0.03 per share, compared to a net loss of $22.9 million, or $4.88 per share, for Q3 2024 [12][21]. Product and Pipeline Developments - YCANTH dispensed 37,642 applicator units in the first nine months of 2025, a 120% increase from 17,119 units in the prior year [2][11]. - The company initiated a global Phase 3 clinical program for YCANTH in common warts, with first patient enrollment expected in the U.S. by the end of 2025 [9][12]. - Positive feedback was received from the FDA regarding the study design for a Phase 3 program for VP-315, an oncology asset targeting basal cell carcinoma [4][12]. Regulatory Milestones - The approval of YCANTH for molluscum in Japan triggered a $10 million milestone payment to Verrica [12][15]. - The European Medicines Agency provided a pathway for YCANTH's registration in Europe without the need for additional Phase 3 studies [4][12]. Strategic Partnerships - Verrica's collaboration with Torii Pharmaceutical includes a 50/50 cost-sharing agreement for the global Phase 3 program, with Torii funding the first $40 million of trial costs [12][15]. - The company is exploring potential partnerships and non-dilutive financing discussions to support further development and commercialization of its late-stage programs [2][12].

Core Insights - Verrica Pharmaceuticals has presented new data from its Phase 2 study of VP-315, an oncolytic peptide immunotherapy, showing its potential to reprogram the tumor microenvironment and enhance immune response in basal cell carcinoma patients [1][2][3] Study Overview - VP-315 is administered intratumorally and aims to induce immunogenic tumor cell death while promoting anti-tumor immune responses [3] - The Phase 2 study involved 82 subjects with 92 tumors, receiving daily injections of 8 mg VP-315 for 2-3 consecutive days [3] Clinical Outcomes - VP-315 demonstrated a 51% complete histologic clearance rate and an overall 97% objective response rate [5] - The treatment was well-tolerated, with no serious adverse events reported [5] - Patients experienced an 86% overall reduction in tumor size, with a 71% reduction in those with residual carcinomas [5] Immune Microenvironment Analysis - The treatment resulted in significant increases in CD3+, CD3+/CD4+, and CD3+/CD8+ T cell densities, indicating enhanced immune activation [11] - There was also an increase in B-cell infiltration, suggesting activation of humoral immunity [11] - The findings indicate a shift from an immunosuppressive to an anti-tumor state in the tumor microenvironment [6][11] Market Potential - The company views VP-315 as a potential first-in-class, non-surgical immunotherapy for basal cell carcinoma, addressing a significant unmet need in dermatologic oncology [2][8] - The annual incidence of basal cell carcinoma in the U.S. is approximately 3.6 million, highlighting the market opportunity for new treatment options [8]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Luminar Technologies, Inc., urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Luminar may seek corporate governance reforms, the return of funds to the company, court-approved financial incentive awards, or other relief and benefits [2][3]. - Shareholder involvement is emphasized as a means to improve company policies, practices, and oversight mechanisms, ultimately enhancing shareholder value [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA), urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Verrica may seek corporate governance reforms, the return of funds to the company, court-approved financial incentive awards, or other relief and benefits [2][3]. - Shareholder involvement is emphasized as a means to improve company policies, practices, and oversight mechanisms, ultimately enhancing shareholder value [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - AlphaVest Acquisition Corp (ATMV) is up 71% at $14.24 [3] - BranchOut Food Inc. (BOF) is up 44% at $3.04 [3] - rYojbaba Co., Ltd. (RYOJ) is up 35% at $5.14 [3] - GSI Technology, Inc. (GSIT) is up 25% at $16.24 [3] - Jowell Global Ltd. (JWEL) is up 18% at $2.02 [3] - General Motors Company (GM) is up 9% at $63.68 [3] - Crown Holdings, Inc. (CCK) is up 8% at $103.00 [3] - Spero Therapeutics, Inc. (SPRO) is up 8% at $2.49 [3] - Sunrun Inc. (RUN) is up 6% at $21.90 [3] - Foxx Development Holdings Inc. (FOXX) is up 5% at $4.50 [3] Premarket Losers - Neuphoria Therapeutics Inc. (NEUP) is down 66% at $5.19 [4] - New Era Energy & Digital, Inc. (NUAI) is down 9% at $5.09 [4] - Odyssey Marine Exploration, Inc. (OMEX) is down 8% at $3.28 [4] - Carbon Revolution Public Limited Company (CREV) is down 7% at $4.86 [4] - Coeur Mining, Inc. (CDE) is down 7% at $20.38 [4] - Hecla Mining Company (HL) is down 6% at $13.50 [4] - Verrica Pharmaceuticals Inc. (VRCA) is down 6% at $4.12 [4] - Sensei Biotherapeutics, Inc. (SNSE) is down 5% at $10.06 [4] - Whitehawk Therapeutics, Inc. (WHWK) is down 5% at $2.52 [4] - Greenidge Generation Holdings Inc. (GREE) is down 5% at $2.07 [4]